Ramelteon: what did the insomnia trial show?
451 adults with chronic primary insomnia were randomized to ramelteon 8 mg or placebo, 30 minutes before bedtime nightly for six months.
Laboratory-measured sleep onset improved at every reported treatment assessment. Patient-reported sleep onset improved at week 1, month 1 and month 5, but was not statistically significant at months 3 and 6. Most adverse events were mild or moderate.
Objective and subjective findings differed. No next-morning residual effects, rebound or withdrawal were detected in this trial; that does not establish their absence in all users.
These results apply to the studied population, formulation and follow-up.
What might this mean, and what would change the interpretation?
This is a selected trial summary, not a full literature review or formal quality appraisal.
What would clarify this: Further studies of long-term outcomes and different patient groups.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.